Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II ctDNA-guided adjuvant chemotherapy study after radical resection of pancreatic cancer
ChiCTR2000033479Phase 2Not yet recruiting
- Sponsor
- Huadong Hospital, Fudan University
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of gemcitabine and paclitaxel in pancreatic cancer (PC) and pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Huadong Hospital, Fudan University. Primary endpoints: Disease-free survival and ctDNA KRAS mutation status. Planned start Jan 2021; status: not yet recruiting.
02
Drugs
gemcitabinepaclitaxel
03
Conditions
pancreatic cancer (PC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR2000033479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000033479.